TABLE 2.
Results of subgroup analysis.
| Outcome or subgroup | Studies | Participants | MD/RR (95%CI) | Z | P | Heterogeneity | |
|---|---|---|---|---|---|---|---|
| I 2 | P | ||||||
| 1. Adverse Events | 18 | 4,422 | 0.75 (0.44, 1.25) | 1.11 | 0.27 | 51% | 0.007 |
| Treatment duration | |||||||
| ≤2 months | 9 | 844 | 0.99 (0.35, 2.83) | 0.02 | 0.98 | 57% | 0.02 |
| 3 months | 4 | 452 | 0.95 (0.41, 2.21) | 0.12 | 0.91 | 0% | 0.48 |
| 6 months | 3 | 350 | 0.26 (0.12, 0.55) | 3.54 | 0.0004 | 0% | 0.53 |
| 12 months | 2 | 2,776 | 1.02 (0.87, 1.20) | 0.24 | 0.81 | 0% | 0.33 |
| 2. Angina Pectoris Frequency | 13 | 1,304 | −2.83 (−3.62, −2.05) | 7.07 | <0.00001 | 99% | <0.00001 |
| Treatment duration | |||||||
| <2 months | 5 | 505 | −2.74 (−2.89, −2.58) | 34.84 | <0.00001 | 39% | 0.16 |
| 2 months | 2 | 146 | −0.65 (−0.90, −0.39) | 5.00 | <0.00001 | 76% | 0.04 |
| 3 months | 5 | 539 | −1.62 (−2.02, −1.22) | 7.95 | <0.00001 | 42% | 0.14 |
| 24 months | 1 | 114 | −20.12 (−21.95, −18.29) | 21.49 | <0.00001 | — | — |
| 3. Angina Pectoris Duration | 8 | 728 | −1.32 (−2.04, −0.61) | 3.63 | 0.0003 | 100% | <0.00001 |
| Treatment duration | |||||||
| <2 months | 3 | 292 | −2.17 (−2.34, −2.00) | 24.56 | <0.00001 | 81% | 0.005 |
| 2 months | 2 | 146 | −0.60 (−1.17, −0.03) | 2.06 | 0.04 | 98% | <0.00001 |
| 3 months | 3 | 290 | −1.04 (−1.34, −0.73) | 6.68 | <0.00001 | 71% | 0.03 |
| 4. LVEF | 8 | 699 | 4.88 (3.19, 6.57) | 5.66 | <0.00001 | 65% | 0.005 |
| Treatment duration | |||||||
| ≤2 months | 3 | 270 | 5.65 (3.58, 7.72) | 5.34 | <0.00001 | 33% | 0.22 |
| 3 months | 3 | 251 | 5.59 (3.41, 7.77) | 5.03 | <0.00001 | 26% | 0.26 |
| 6 months | 2 | 178 | 3.50 (−1.47, 8.47) | 1.38 | 0.17 | 87% | 0.005 |
| 5. TC | 7 | 734 | −0.59 (−0.78, −0.40) | 6.03 | <0.00001 | 82% | <0.00001 |
| Treatment duration | |||||||
| ≤2 months | 3 | 319 | −0.63 (−0.98, −0.27) | 3.44 | 0.0006 | 83% | 0.003 |
| 3 months | 2 | 205 | −0.36 (−0.65, −0.07) | 2.40 | 0.02 | 52% | 0.15 |
| ≥6 months | 2 | 210 | −0.75 (−0.93, −0.58) | 8.56 | <0.00001 | 0% | 0.36 |
| 6. TG | 8 | 798 | −0.36 (−0.53, −0.19) | 4.17 | <0.0001 | 87% | <0.00001 |
| Treatment duration | |||||||
| 1 month | 2 | 241 | −0.55 (−0.91, −0.20) | 3.07 | 0.002 | 92% | 0.0006 |
| 2 months | 2 | 142 | −0.26 (−0.36, −0.17) | 5.46 | <0.00001 | 0% | 0.44 |
| 3 months | 2 | 205 | −0.18 (−0.69, 0.34) | 0.66 | 0.51 | 93% | <0.0001 |
| ≥6 months | 2 | 210 | −0.55 (−1.13, 0.03) | 1.87 | 0.06 | 79% | 0.03 |
| 7. LDL-C | 8 | 798 | −0.35 (−0.44, −0.25) | 7.01 | <0.00001 | 77% | <0.0001 |
| Treatment duration | |||||||
| 1 month | 2 | 241 | −0.45 (−0.59, −0.31) | 6.22 | <0.00001 | 61% | 0.11 |
| 2 months | 2 | 142 | −0.32 (−0.58, −0.06) | 2.38 | 0.02 | 65% | 0.09 |
| 3 months | 2 | 205 | −0.32 (−0.39, −0.24) | 8.18 | <0.00001 | 0% | 0.89 |
| ≥6 months | 2 | 210 | −0.33 (−0.45, −0.21) | 5.37 | <0.00001 | 0% | 0.37 |
| 8. HDL-C | 4 | 446 | 0.31 (0.08, 0.54) | 2.61 | 0.009 | 96% | <0.0001 |
| Treatment duration | |||||||
| 1 month | 2 | 241 | 0.40 (−0.02, 0.82) | 1.86 | 0.06 | 97% | <0.00001 |
| 3 months | 2 | 205 | 0.22 (−0.05, 0.50) | 1.59 | 0.11 | 94% | <0.00001 |
CI, confidence interval; MD, mean difference; RR, risk ratio; LVEF, left ventricular ejection fraction; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.